title: NICE guidance on pixantrone monotherapy for multiply relapsed or refractory aggressive non-Hodgkin lymphoma.
authors.forename: Linda J
authors.initials: LJ
authors.lastname: Landells
authors.forename: Carl
authors.initials: C
authors.lastname: Prescott
authors.forename: Nicola
authors.initials: N
authors.lastname: Hay
authors.forename: Frances
authors.initials: F
authors.lastname: Sutcliffe
authors.forename: Andrew
authors.initials: A
authors.lastname: Stevens
mesh_terms: D003362:Cost-Benefit Analysis; D017277:Drug Approval; D016527:Drug Costs; D019008:Drug Resistance, Neoplasm; D019317:Evidence-Based Medicine; D006801:Humans; D007546:Isoquinolines / Q000009:adverse effects / Q000191:economics / Q000627:therapeutic use*; D008228:Lymphoma, Non-Hodgkin / Q000188:drug therapy* / Q000191:economics / Q000401:mortality / Q000473:pathology; D017410:Practice Guidelines as Topic; D012008:Recurrence; D059005:Topoisomerase II Inhibitors / Q000009:adverse effects / Q000191:economics / Q000627:therapeutic use*; D016896:Treatment Outcome
chemical_list: D007546:Isoquinolines; D059005:Topoisomerase II Inhibitors; C086548:pixantrone